Mergers & acquisitions
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
Amidst a chorus of pushback from scientific and health organizations, Philip Morris International’s $1.4 billion offer now has the backing of Vectura Group’s board.
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.
BioLife will obtain all of the outstanding shares of Sexton that it doesn’t already own for $24 million in consideration for 506,382 newly issued shares of BioLife common stock.
The acquisition of OtiTopic will boost the company’s new strategy and potentially address a significant unmet medical need in more than 83 million people in the U.S. with myocardial infarction.
The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.
Under the terms of the agreement, Bayer is paying $1.5 billion upfront and up to $500 million in various milestone payments.
With its acquisition, Sanofi aims to establish a firm toehold in the mRNA space by integrating dedicated research and development capabilities, chemistry, manufacturing and controls.
Deerfield Management and ARCH Venture Partners have partnered with venture capital firm Section 32 to sponsor DA32 Life Science Tech Acquisition Corp, a blank check company that is today priced for $200 million in an initial public offering (IPO).
PRESS RELEASES